25 XP   0   0   10

NeoGenomics Inc
Buy, Hold or Sell?

Let's analyse Neogenomics together

PenkeI guess you are interested in NeoGenomics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of NeoGenomics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about NeoGenomics Inc

I send you an email if I find something interesting about NeoGenomics Inc.

Quick analysis of Neogenomics (30 sec.)










What can you expect buying and holding a share of Neogenomics? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
20.0%

What is your share worth?

Current worth
$7.38
Expected worth in 1 year
$5.61
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
$-1.77
Return On Investment
-11.6%

For what price can you sell your share?

Current Price per Share
$15.22
Expected price per share
$11.03 - $15.86
How sure are you?
50%

1. Valuation of Neogenomics (5 min.)




Live pricePrice per Share (EOD)

$15.22

Intrinsic Value Per Share

$-7.74 - $-1.59

Total Value Per Share

$-0.37 - $5.79

2. Growth of Neogenomics (5 min.)




Is Neogenomics growing?

Current yearPrevious yearGrowGrow %
How rich?$941.5m$998m-$56.4m-6.0%

How much money is Neogenomics making?

Current yearPrevious yearGrowGrow %
Making money-$87.9m-$144.2m$56.2m64.0%
Net Profit Margin-14.9%-28.3%--

How much money comes from the company's main activities?

3. Financial Health of Neogenomics (5 min.)




4. Comparing to competitors in the Diagnostics & Research industry (5 min.)




  Industry Rankings (Diagnostics & Research)  


Richest
#34 / 145

Most Revenue
#51 / 145

Most Profit
#123 / 145

What can you expect buying and holding a share of Neogenomics? (5 min.)

Welcome investor! Neogenomics's management wants to use your money to grow the business. In return you get a share of Neogenomics.

What can you expect buying and holding a share of Neogenomics?

First you should know what it really means to hold a share of Neogenomics. And how you can make/lose money.

Speculation

The Price per Share of Neogenomics is $15.22. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Neogenomics.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Neogenomics, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $7.38. Based on the TTM, the Book Value Change Per Share is $-0.44 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.86 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Neogenomics.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.69-4.5%-0.69-4.5%-1.13-7.4%-0.36-2.4%-0.21-1.4%
Usd Book Value Change Per Share-0.44-2.9%-0.44-2.9%-0.86-5.7%0.976.4%0.724.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.080.5%
Usd Total Gains Per Share-0.44-2.9%-0.44-2.9%-0.86-5.7%0.976.4%0.805.2%
Usd Price Per Share16.18-16.18-9.24-28.53-18.47-
Price to Earnings Ratio-23.47--23.47--8.17-311.95-178.10-
Price-to-Total Gains Ratio-36.55--36.55--10.69-4.00-14.21-
Price to Book Ratio2.19-2.19-1.18-4.91-5.40-
Price-to-Total Gains Ratio-36.55--36.55--10.69-4.00-14.21-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share15.22
Number of shares65
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.440.97
Usd Total Gains Per Share-0.440.97
Gains per Quarter (65 shares)-28.7763.27
Gains per Year (65 shares)-115.09253.09
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-115-1250253243
20-230-2400506496
30-345-3550759749
40-460-470010121002
50-575-585012651255
60-691-700015191508
70-806-815017721761
80-921-930020252014
90-1036-1045022782267
100-1151-1160025312520

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%4.06.00.040.0%6.018.00.025.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%7.03.00.070.0%15.09.00.062.5%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%2.00.08.020.0%2.00.022.08.3%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%8.02.00.080.0%16.08.00.066.7%

Fundamentals of Neogenomics

About NeoGenomics Inc

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Fundamental data was last updated by Penke on 2024-04-11 15:43:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of NeoGenomics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Neogenomics earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Neogenomics to the Diagnostics & Research industry mean.
  • A Net Profit Margin of -14.9% means that $-0.15 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of NeoGenomics Inc:

  • The MRQ is -14.9%. The company is making a huge loss. -2
  • The TTM is -14.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-14.9%TTM-14.9%0.0%
TTM-14.9%YOY-28.3%+13.4%
TTM-14.9%5Y-8.4%-6.5%
5Y-8.4%10Y-4.5%-3.9%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.9%-7.3%-7.6%
TTM-14.9%-6.7%-8.2%
YOY-28.3%-1.9%-26.4%
5Y-8.4%-1.5%-6.9%
10Y-4.5%-3.4%-1.1%
1.1.2. Return on Assets

Shows how efficient Neogenomics is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Neogenomics to the Diagnostics & Research industry mean.
  • -5.2% Return on Assets means that Neogenomics generated $-0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of NeoGenomics Inc:

  • The MRQ is -5.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -5.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.2%TTM-5.2%0.0%
TTM-5.2%YOY-8.3%+3.1%
TTM-5.2%5Y-2.5%-2.7%
5Y-2.5%10Y-1.3%-1.2%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.2%-1.3%-3.9%
TTM-5.2%-1.3%-3.9%
YOY-8.3%-0.9%-7.4%
5Y-2.5%-0.5%-2.0%
10Y-1.3%-0.9%-0.4%
1.1.3. Return on Equity

Shows how efficient Neogenomics is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Neogenomics to the Diagnostics & Research industry mean.
  • -9.3% Return on Equity means Neogenomics generated $-0.09 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of NeoGenomics Inc:

  • The MRQ is -9.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -9.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.3%TTM-9.3%0.0%
TTM-9.3%YOY-14.5%+5.1%
TTM-9.3%5Y-4.5%-4.9%
5Y-4.5%10Y-2.4%-2.1%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.3%-0.5%-8.8%
TTM-9.3%0.2%-9.5%
YOY-14.5%-0.1%-14.4%
5Y-4.5%-1.4%-3.1%
10Y-2.4%-2.3%-0.1%

1.2. Operating Efficiency of NeoGenomics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Neogenomics is operating .

  • Measures how much profit Neogenomics makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Neogenomics to the Diagnostics & Research industry mean.
  • An Operating Margin of -13.4% means the company generated $-0.13  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of NeoGenomics Inc:

  • The MRQ is -13.4%. The company is operating very inefficient. -2
  • The TTM is -13.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-13.4%TTM-13.4%0.0%
TTM-13.4%YOY-30.0%+16.7%
TTM-13.4%5Y-8.8%-4.6%
5Y-8.8%10Y-3.8%-5.0%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.4%-7.4%-6.0%
TTM-13.4%0.5%-13.9%
YOY-30.0%4.0%-34.0%
5Y-8.8%3.7%-12.5%
10Y-3.8%-1.3%-2.5%
1.2.2. Operating Ratio

Measures how efficient Neogenomics is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • An Operation Ratio of 1.16 means that the operating costs are $1.16 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of NeoGenomics Inc:

  • The MRQ is 1.163. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.163. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.163TTM1.1630.000
TTM1.163YOY1.300-0.137
TTM1.1635Y1.142+0.022
5Y1.14210Y1.067+0.075
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1631.280-0.117
TTM1.1631.304-0.141
YOY1.3001.236+0.064
5Y1.1421.242-0.100
10Y1.0671.205-0.138

1.3. Liquidity of NeoGenomics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Neogenomics is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A Current Ratio of 6.20 means the company has $6.20 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of NeoGenomics Inc:

  • The MRQ is 6.197. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.197. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.197TTM6.1970.000
TTM6.197YOY6.731-0.533
TTM6.1975Y6.284-0.087
5Y6.28410Y4.335+1.949
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ6.1972.122+4.075
TTM6.1972.298+3.899
YOY6.7312.599+4.132
5Y6.2843.012+3.272
10Y4.3353.081+1.254
1.3.2. Quick Ratio

Measures if Neogenomics is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Neogenomics to the Diagnostics & Research industry mean.
  • A Quick Ratio of 6.43 means the company can pay off $6.43 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of NeoGenomics Inc:

  • The MRQ is 6.429. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.429. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.429TTM6.4290.000
TTM6.429YOY8.145-1.716
TTM6.4295Y6.931-0.502
5Y6.93110Y4.482+2.450
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4291.215+5.214
TTM6.4291.319+5.110
YOY8.1451.661+6.484
5Y6.9311.957+4.974
10Y4.4822.295+2.187

1.4. Solvency of NeoGenomics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Neogenomics assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Neogenomics to Diagnostics & Research industry mean.
  • A Debt to Asset Ratio of 0.44 means that Neogenomics assets are financed with 44.0% credit (debt) and the remaining percentage (100% - 44.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of NeoGenomics Inc:

  • The MRQ is 0.440. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.440. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.440TTM0.4400.000
TTM0.440YOY0.426+0.014
TTM0.4405Y0.371+0.069
5Y0.37110Y0.368+0.003
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4400.429+0.011
TTM0.4400.407+0.033
YOY0.4260.394+0.032
5Y0.3710.450-0.079
10Y0.3680.450-0.082
1.4.2. Debt to Equity Ratio

Measures if Neogenomics is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Neogenomics to the Diagnostics & Research industry mean.
  • A Debt to Equity ratio of 78.6% means that company has $0.79 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of NeoGenomics Inc:

  • The MRQ is 0.786. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.786. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.786TTM0.7860.000
TTM0.786YOY0.743+0.042
TTM0.7865Y0.608+0.178
5Y0.60810Y0.598+0.010
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7860.606+0.180
TTM0.7860.571+0.215
YOY0.7430.631+0.112
5Y0.6080.658-0.050
10Y0.5980.734-0.136

2. Market Valuation of NeoGenomics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Neogenomics generates.

  • Above 15 is considered overpriced but always compare Neogenomics to the Diagnostics & Research industry mean.
  • A PE ratio of -23.47 means the investor is paying $-23.47 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of NeoGenomics Inc:

  • The EOD is -22.079. Based on the earnings, the company is expensive. -2
  • The MRQ is -23.471. Based on the earnings, the company is expensive. -2
  • The TTM is -23.471. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-22.079MRQ-23.471+1.393
MRQ-23.471TTM-23.4710.000
TTM-23.471YOY-8.174-15.297
TTM-23.4715Y311.953-335.424
5Y311.95310Y178.097+133.856
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-22.079-0.239-21.840
MRQ-23.471-0.395-23.076
TTM-23.471-0.199-23.272
YOY-8.174-0.008-8.166
5Y311.9533.483+308.470
10Y178.0974.432+173.665
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of NeoGenomics Inc:

  • The EOD is -63.254. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -67.244. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -67.244. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-63.254MRQ-67.244+3.990
MRQ-67.244TTM-67.2440.000
TTM-67.244YOY-12.170-55.074
TTM-67.2445Y148.321-215.565
5Y148.32110Y146.704+1.617
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD-63.254-0.296-62.958
MRQ-67.244-0.441-66.803
TTM-67.244-1.480-65.764
YOY-12.170-2.079-10.091
5Y148.321-1.665+149.986
10Y146.704-1.971+148.675
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Neogenomics is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A PB ratio of 2.19 means the investor is paying $2.19 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of NeoGenomics Inc:

  • The EOD is 2.063. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.193. Based on the equity, the company is underpriced. +1
  • The TTM is 2.193. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.063MRQ2.193-0.130
MRQ2.193TTM2.1930.000
TTM2.193YOY1.181+1.011
TTM2.1935Y4.911-2.718
5Y4.91110Y5.397-0.486
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD2.0631.962+0.101
MRQ2.1932.222-0.029
TTM2.1932.168+0.025
YOY1.1813.041-1.860
5Y4.9113.534+1.377
10Y5.3974.125+1.272
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of NeoGenomics Inc.

3.1. Institutions holding NeoGenomics Inc

Institutions are holding 100.865% of the shares of NeoGenomics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BlackRock Inc15.65790.008219980993-121915-0.6065
2023-12-31Vanguard Group Inc11.10390.00514169665-146536-1.0236
2023-12-31Brown Advisory Holdings Inc7.55710.21939643599139739716.9459
2023-12-31T. Rowe Price Investment Management,Inc.5.00160.0672638251585629615.4952
2023-12-31HHG PLC4.9750.06136348613-825814-11.5105
2023-12-31State Street Corporation3.79670.00384844945-79544-1.6153
2023-12-31Goldman Sachs Group Inc3.58460.00664574290210715485.4089
2023-12-31Macquarie Group Ltd3.19820.07634081179106222635.1852
2023-09-30Greenhouse Funds LLLP3.11973.6199398100368618620.8262
2023-12-31First Light Asset Management, LLC3.07725.1116392675689784329.6424
2023-12-31Dimensional Fund Advisors, Inc.2.3560.01423006523186030.6226
2023-12-31Geode Capital Management, LLC2.21810.004828305351243214.5939
2023-12-31Schroder Investment Management Group1.94380.0522480424-32883-1.3084
2023-12-31American Century Companies Inc1.560.0221199069219638107305.2972
2023-12-31Morgan Stanley - Brokerage Accounts1.53950.00281964566-30882-1.5476
2023-12-31Emerald Advisers, LLC1.48721.31421897814-29260-1.5184
2023-12-31Fred Alger Management, LLC1.470.1638187583054413040.8598
2023-12-31Amvescap Plc.1.32780.00651694459-64676-3.6766
2023-12-31Northern Trust Corp1.25280.00471598640224981.4274
2023-12-31Emerald Mutual Fund Advisers Trust1.22081.3347155789500
Total 77.447912.09998830936+8348954+8.4%

3.2. Funds holding NeoGenomics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29iShares Core S&P Small-Cap ETF6.80380.17488682389129960.1499
2024-02-29Vanguard Total Stock Mkt Idx Inv3.13190.0043996590-96167-2.3497
2024-02-29Vanguard Small Cap Index2.57470.03653285586304700.9361
2024-02-29iShares Russell 2000 ETF2.41350.07713079880-503-0.0163
2024-02-29Brown Advisory Small-Cap Growth Inv2.38862.1219304808700
2023-12-31T. Rowe Price Small-Cap Stock2.29670.5011293080035980013.9946
2023-12-31T. Rowe Price US Small-Cap Core Equity2.29670.4999293080035980013.9946
2023-12-31Macquarie US Small Cap Core Equity1.93430.5343246839200
2024-01-31Delaware Small Cap Core I1.91140.51192439153-29239-1.1845
2023-12-31Janus Henderson US SMID Cap Growth1.8770.5707239522300
2023-12-31Janus Henderson Triton D1.8770.5683239522300
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.47670.0288188440214020.0745
2024-02-29Vanguard Small Cap Growth Index Inv1.44510.08241844080306561.6905
2023-12-31American Century Small Cap Growth Inv1.42610.9187181979318197930
2023-12-31American Century U.S. Small Cap Growth1.42610.9189181979318197930
2024-02-29Principal SmallCap Growth I Instl1.22380.971561720-106-0.0068
2023-12-31T. Rowe Price U.S. SC Core Eq Tr-Z1.12110.4961143061321270017.4643
2023-12-31T. Rowe Price Instl Small-Cap Stock1.06630.5003136068019800017.0296
2023-12-31Janus Henderson Venture D1.04040.7132770500
2023-12-31Janus Henderson US Small Cap Growth1.04040.7048132770500
Total 40.771610.920552028614+4719395+9.1%

3.3. Insider Transactions

Insiders are holding 1.215% of the shares of NeoGenomics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-15Alicia C OlivoSELL258714.96
2023-11-17Alicia C OlivoSELL266918.39

4. Summary

4.1. Key Performance Indicators

The key performance indicators of NeoGenomics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.443-0.4430%-0.864+95%0.973-145%0.721-161%
Book Value Per Share--7.3787.3780%7.821-6%6.660+11%4.122+79%
Current Ratio--6.1976.1970%6.731-8%6.284-1%4.335+43%
Debt To Asset Ratio--0.4400.4400%0.426+3%0.371+19%0.368+20%
Debt To Equity Ratio--0.7860.7860%0.743+6%0.608+29%0.598+31%
Dividend Per Share----0%-0%-0%0.076-100%
Eps---0.689-0.6890%-1.130+64%-0.358-48%-0.208-70%
Free Cash Flow Per Share---0.241-0.2410%-0.759+216%-0.380+58%-0.144-40%
Free Cash Flow To Equity Per Share---0.205-0.2050%-0.667+225%1.401-115%0.864-124%
Gross Profit Margin--1.8051.8050%1.467+23%-0.723+140%1.740+4%
Intrinsic Value_10Y_max---1.590--------
Intrinsic Value_10Y_min---7.744--------
Intrinsic Value_1Y_max---0.148--------
Intrinsic Value_1Y_min---0.629--------
Intrinsic Value_3Y_max---0.453--------
Intrinsic Value_3Y_min---2.028--------
Intrinsic Value_5Y_max---0.769--------
Intrinsic Value_5Y_min---3.568--------
Market Cap1942224200.000-6%2064729800.0002064729800.0000%1179116400.000+75%3640202860.000-43%2357084310.000-12%
Net Profit Margin---0.149-0.1490%-0.283+90%-0.084-44%-0.045-70%
Operating Margin---0.134-0.1340%-0.300+125%-0.088-34%-0.038-72%
Operating Ratio--1.1631.1630%1.300-11%1.142+2%1.067+9%
Pb Ratio2.063-6%2.1932.1930%1.181+86%4.911-55%5.397-59%
Pe Ratio-22.079+6%-23.471-23.4710%-8.174-65%311.953-108%178.097-113%
Price Per Share15.220-6%16.18016.1800%9.240+75%28.526-43%18.471-12%
Price To Free Cash Flow Ratio-63.254+6%-67.244-67.2440%-12.170-82%148.321-145%146.704-146%
Price To Total Gains Ratio-34.384+6%-36.553-36.5530%-10.695-71%3.999-1014%14.212-357%
Quick Ratio--6.4296.4290%8.145-21%6.931-7%4.482+43%
Return On Assets---0.052-0.0520%-0.083+58%-0.025-53%-0.013-75%
Return On Equity---0.093-0.0930%-0.145+55%-0.045-52%-0.024-74%
Total Gains Per Share---0.443-0.4430%-0.864+95%0.973-145%0.797-156%
Usd Book Value--941537000.000941537000.0000%998023000.000-6%849907800.000+11%526062800.000+79%
Usd Book Value Change Per Share---0.443-0.4430%-0.864+95%0.973-145%0.721-161%
Usd Book Value Per Share--7.3787.3780%7.821-6%6.660+11%4.122+79%
Usd Dividend Per Share----0%-0%-0%0.076-100%
Usd Eps---0.689-0.6890%-1.130+64%-0.358-48%-0.208-70%
Usd Free Cash Flow---30705000.000-30705000.0000%-96884000.000+216%-48550000.000+58%-18413000.000-40%
Usd Free Cash Flow Per Share---0.241-0.2410%-0.759+216%-0.380+58%-0.144-40%
Usd Free Cash Flow To Equity Per Share---0.205-0.2050%-0.667+225%1.401-115%0.864-124%
Usd Market Cap1942224200.000-6%2064729800.0002064729800.0000%1179116400.000+75%3640202860.000-43%2357084310.000-12%
Usd Price Per Share15.220-6%16.18016.1800%9.240+75%28.526-43%18.471-12%
Usd Profit---87968000.000-87968000.0000%-144250000.000+64%-45677400.000-48%-23371900.000-73%
Usd Revenue--591643000.000591643000.0000%509728000.000+16%487795600.000+21%340528400.000+74%
Usd Total Gains Per Share---0.443-0.4430%-0.864+95%0.973-145%0.797-156%
 EOD+3 -5MRQTTM+0 -0YOY+24 -105Y+12 -2210Y+11 -25

4.2. Fundamental Score

Let's check the fundamental score of NeoGenomics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-22.079
Price to Book Ratio (EOD)Between0-12.063
Net Profit Margin (MRQ)Greater than0-0.149
Operating Margin (MRQ)Greater than0-0.134
Quick Ratio (MRQ)Greater than16.429
Current Ratio (MRQ)Greater than16.197
Debt to Asset Ratio (MRQ)Less than10.440
Debt to Equity Ratio (MRQ)Less than10.786
Return on Equity (MRQ)Greater than0.15-0.093
Return on Assets (MRQ)Greater than0.05-0.052
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of NeoGenomics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.614
Ma 20Greater thanMa 5014.297
Ma 50Greater thanMa 10015.027
Ma 100Greater thanMa 20015.852
OpenGreater thanClose14.340
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-12-312020-12-312021-12-312022-12-312023-12-31
Net Interest Income  -3,713-3,306-7,0191,937-5,0823,576-1,50611,5019,995



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,681,229
Total Liabilities739,692
Total Stockholder Equity941,537
 As reported
Total Liabilities 739,692
Total Stockholder Equity+ 941,537
Total Assets = 1,681,229

Assets

Total Assets1,681,229
Total Current Assets596,812
Long-term Assets1,084,417
Total Current Assets
Cash And Cash Equivalents 342,488
Short-term Investments 72,715
Net Receivables 131,227
Inventory 24,156
Other Current Assets 8,239
Total Current Assets  (as reported)596,812
Total Current Assets  (calculated)578,825
+/- 17,987
Long-term Assets
Property Plant Equipment 183,781
Goodwill 522,766
Intangible Assets 373,128
Long-term Assets Other 4,742
Long-term Assets  (as reported)1,084,417
Long-term Assets  (calculated)1,084,417
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities96,304
Long-term Liabilities643,388
Total Stockholder Equity941,537
Total Current Liabilities
Short-term Debt 5,610
Accounts payable 20,334
Other Current Liabilities 68,230
Total Current Liabilities  (as reported)96,304
Total Current Liabilities  (calculated)94,174
+/- 2,130
Long-term Liabilities
Long term Debt 538,198
Capital Lease Obligations 73,481
Long-term Liabilities Other 13,034
Long-term Liabilities  (as reported)643,388
Long-term Liabilities  (calculated)624,713
+/- 18,675
Total Stockholder Equity
Common Stock127
Retained Earnings -247,055
Accumulated Other Comprehensive Income -1,674
Other Stockholders Equity 1,190,139
Total Stockholder Equity (as reported)941,537
Total Stockholder Equity (calculated)941,537
+/-0
Other
Capital Stock127
Cash and Short Term Investments 415,203
Common Stock Shares Outstanding 125,502
Current Deferred Revenue2,130
Liabilities and Stockholders Equity 1,681,229
Net Debt 269,191
Net Invested Capital 1,479,735
Net Working Capital 500,508
Property Plant and Equipment Gross 341,992
Short Long Term Debt Total 611,679



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-31
> Total Assets 
0
81
448
507
592
1,080
3,132
6,521
7,295
12,945
13,651
19,949
30,071
39,916
81,106
367,955
337,118
343,340
505,015
709,506
988,331
1,869,778
1,740,034
1,681,229
1,681,2291,740,0341,869,778988,331709,506505,015343,340337,118367,95581,10639,91630,07119,94913,65112,9457,2956,5213,1321,080592507448810
   > Total Current Assets 
0
79
61
102
196
681
1,896
4,152
4,356
8,520
8,738
13,178
18,581
27,491
58,742
99,028
78,825
84,963
103,668
290,738
448,730
681,508
605,291
596,812
596,812605,291681,508448,730290,738103,66884,96378,82599,02858,74227,49118,58113,1788,7388,5204,3564,1521,89668119610261790
       Cash And Cash Equivalents 
0
77
0
25
113
11
126
211
468
1,631
1,097
2,628
1,868
4,834
33,689
23,420
12,525
12,821
9,811
173,016
228,713
316,827
263,180
342,488
342,488263,180316,827228,713173,0169,81112,82112,52523,42033,6894,8341,8682,6281,0971,63146821112611113250770
       Short-term Investments 
0
0
0
0
0
0
0
0
0
1,000
500
500
0
0
0
0
0
0
0
0
67,546
198,563
174,809
72,715
72,715174,809198,56367,546000000005005001,000000000000
       Net Receivables 
0
0
40
64
56
551
1,550
3,237
2,914
4,632
5,236
7,894
14,034
18,653
20,475
48,943
55,512
60,427
76,919
94,242
106,843
112,130
119,711
131,227
131,227119,711112,130106,84394,24276,91960,42755,51248,94320,47518,65314,0347,8945,2364,6322,9143,2371,55055156644000
       Other Current Assets 
0
1
2
3
12
59
102
400
482
655
1,018
954
820
4,004
4,578
4,889
4,535
4,241
561
9,075
4,555
8,189
8,077
8,239
8,2398,0778,1894,5559,0755614,2414,5354,8894,5784,0048209541,01865548240010259123210
   > Long-term Assets 
0
3
386
405
396
400
1,236
2,369
2,940
4,425
4,913
6,771
11,490
12,425
22,364
268,927
258,293
258,377
401,347
418,768
539,601
1,188,270
1,134,743
1,084,417
1,084,4171,134,7431,188,270539,601418,768401,347258,377258,293268,92722,36412,42511,4906,7714,9134,4252,9402,3691,23640039640538630
       Property Plant Equipment 
0
3
383
398
393
382
1,202
2,108
2,875
4,340
4,839
6,642
8,607
9,694
15,082
34,577
34,036
36,504
60,888
90,680
151,888
211,662
198,608
183,781
183,781198,608211,662151,88890,68060,88836,50434,03634,57715,0829,6948,6076,6424,8394,3402,8752,1081,20238239339838330
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
2,800
2,577
2,929
146,421
147,019
147,019
197,892
198,601
211,083
527,115
522,766
522,766
522,766522,766527,115211,083198,601197,892147,019147,019146,4212,9292,5772,800000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
400
500
0
29,555
0
0
0
00029,555050040000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
2,800
2,577
4,212
87,800
77,064
74,165
140,029
126,640
120,653
442,325
408,260
373,128
373,128408,260442,325120,653126,640140,02974,16577,06487,8004,2122,5772,800000000000000
       Other Assets 
0
0
4
7
3
17
34
261
65
85
74
129
0
154
141
129
174
491
2,038
2,847
54,446
7,168
5,109
0
05,1097,16854,4462,8472,0384911741291411540129748565261341737400
> Total Liabilities 
125
186
424
875
1,019
2,075
3,077
4,199
5,794
7,302
10,516
14,052
20,855
18,205
20,701
129,843
150,522
137,807
184,572
202,098
294,037
761,501
742,011
739,692
739,692742,011761,501294,037202,098184,572137,807150,522129,84320,70118,20520,85514,05210,5167,3025,7944,1993,0772,0751,019875424186125
   > Total Current Liabilities 
125
186
424
285
1,019
666
2,628
3,362
4,391
5,776
9,168
11,444
17,758
14,323
14,623
40,058
59,912
35,065
60,925
63,904
73,183
87,232
89,932
96,304
96,30489,93287,23273,18363,90460,92535,06559,91240,05814,62314,32317,75811,4449,1685,7764,3913,3622,6286661,019285424186125
       Short-term Debt 
0
0
14
46
72
0
94
243
1,784
2,034
5,437
6,005
10,670
7,068
3,224
14,003
30,532
8,989
14,171
13,813
7,808
8,019
6,654
5,610
5,6106,6548,0197,80813,81314,1718,98930,53214,0033,2247,06810,6706,0055,4372,0341,78424394072461400
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
66
600
3,842
3,799
7,873
5,000
0
0
0
0
00005,0007,8733,7993,8426006600000000000000
       Accounts payable 
10
19
120
70
96
464
698
1,799
1,512
1,969
1,933
2,529
3,611
4,177
6,294
26,055
29,380
26,076
17,779
50,091
65,375
17,921
83,278
20,334
20,33483,27817,92165,37550,09117,77926,07629,38026,0556,2944,1773,6112,5291,9331,9691,5121,79969846496701201910
       Other Current Liabilities 
115
167
191
59
740
102
1,636
375
1,095
1,773
1,798
2,910
3,477
3,078
5,105
13,591
12,598
15,626
28,048
-1,610
-4,029
56,100
-7,557
68,230
68,230-7,55756,100-4,029-1,61028,04815,62612,59813,5915,1053,0783,4772,9101,7981,7731,0953751,63610274059191167115
   > Long-term Liabilities 
10
19
233
590
206
1,409
449
837
1,403
1,526
1,348
2,608
3,097
3,882
6,078
89,785
90,610
102,742
123,647
138,194
220,854
674,269
652,079
643,388
643,388652,079674,269220,854138,194123,647102,74290,61089,7856,0783,8823,0972,6081,3481,5261,4038374491,4092065902331910
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
2,608
3,097
3,294
5,257
5,040
97,326
96,415
98,130
115,863
168,120
532,483
535,322
0
0535,322532,483168,120115,86398,13096,41597,3265,0405,2573,2943,0972,60800000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
28,602
22,873
32,615
0
0
0
0
0
0
00000032,61522,87328,602000000000000000
       Other Liabilities 
0
0
0
0
0
1,409
0
0
0
0
0
0
0
0
821
15,741
14,973
6,971
24,617
17,132
10,438
69,497
47,805
0
047,80569,49710,43817,13224,6176,97114,97315,741821000000001,40900000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
588
821
32,409
14,973
6,307
22,457
15,566
5,415
55,475
34,750
0
034,75055,4755,41515,56622,4576,30714,97332,4098215880000000000000
> Total Stockholder Equity
-125
-105
23
-368
-427
-995
55
2,322
1,501
5,643
3,135
5,897
9,216
21,711
60,405
238,112
186,596
205,533
320,443
507,408
694,294
1,108,277
998,023
941,537
941,537998,0231,108,277694,294507,408320,443205,533186,596238,11260,40521,7119,2165,8973,1355,6431,5012,32255-995-427-36823-105-125
   Common Stock
1,322
405
4
18
22
23
27
31
32
37
37
43
45
49
60
76
79
80
94
105
112
124
127
127
1271271241121059480797660494543373732312723221844051,322
   Retained Earnings -247,055-159,087-14,837-7,185-11,357-51,258-57,466-52,460-21,941-19,406-20,538-22,571-22,636-21,459-18,156-15,913-14,530-11,150-11,020-10,023-8,668-8,668-8,078-1,447
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
28,490
31,742
42,200
79,751
231,375
216,104
230,030
372,186
520,278
701,357
1,123,628
1,160,882
0
01,160,8821,123,628701,357520,278372,186230,030216,104231,37579,75142,20031,74228,49000000000000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 
0
11,359
8,726
8,818
9,604
10,005
11,300
16,821
17,382
26,548
29,125
35,142
42,031
56,678
99,573
257,909
243,206
230,030
-132,829
520,278
701,357
1,123,628
1,160,882
1,190,139
1,190,1391,160,8821,123,628701,357520,278-132,829230,030243,206257,90999,57356,67842,03135,14229,12526,54817,38216,82111,30010,0059,6048,8188,72611,3590



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue591,643
Cost of Revenue-347,039
Gross Profit244,604244,604
 
Operating Income (+$)
Gross Profit244,604
Operating Expense-341,252
Operating Income-107,736-96,648
 
Operating Expense (+$)
Research Development27,309
Selling General Administrative243,101
Selling And Marketing Expenses70,842
Operating Expense341,252341,252
 
Net Interest Income (+$)
Interest Income16,902
Interest Expense-6,907
Other Finance Cost-0
Net Interest Income9,995
 
Pretax Income (+$)
Operating Income-107,736
Net Interest Income9,995
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-97,097-97,292
EBIT - interestExpense = -86,009
-97,097
-81,061
Interest Expense6,907
Earnings Before Interest and Taxes (EBIT)-79,102-90,190
Earnings Before Interest and Taxes (EBITDA)-6,519
 
After tax Income (+$)
Income Before Tax-97,097
Tax Provision--9,129
Net Income From Continuing Ops-87,968-87,968
Net Income-87,968
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses688,291
Total Other Income/Expenses Net-10,444-9,995
 

Technical Analysis of Neogenomics
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Neogenomics. The general trend of Neogenomics is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Neogenomics's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of NeoGenomics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 15.46 < 15.57 < 15.86.

The bearish price targets are: 13.34 > 13.33 > 11.03.

Tweet this
NeoGenomics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of NeoGenomics Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

NeoGenomics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of NeoGenomics Inc. The current macd is -0.22431464.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Neogenomics price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Neogenomics. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Neogenomics price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
NeoGenomics Inc Daily Moving Average Convergence/Divergence (MACD) ChartNeoGenomics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of NeoGenomics Inc. The current adx is 13.30.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Neogenomics shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
NeoGenomics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of NeoGenomics Inc. The current sar is 13.41.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
NeoGenomics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of NeoGenomics Inc. The current rsi is 58.61. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
NeoGenomics Inc Daily Relative Strength Index (RSI) ChartNeoGenomics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of NeoGenomics Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Neogenomics price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
NeoGenomics Inc Daily Stochastic Oscillator ChartNeoGenomics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of NeoGenomics Inc. The current cci is 116.91.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
NeoGenomics Inc Daily Commodity Channel Index (CCI) ChartNeoGenomics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of NeoGenomics Inc. The current cmo is 32.50.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
NeoGenomics Inc Daily Chande Momentum Oscillator (CMO) ChartNeoGenomics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of NeoGenomics Inc. The current willr is -30.62730627.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Neogenomics is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
NeoGenomics Inc Daily Williams %R ChartNeoGenomics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of NeoGenomics Inc.

NeoGenomics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of NeoGenomics Inc. The current atr is 0.69683242.

NeoGenomics Inc Daily Average True Range (ATR) ChartNeoGenomics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of NeoGenomics Inc. The current obv is 21,216,080.

NeoGenomics Inc Daily On-Balance Volume (OBV) ChartNeoGenomics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of NeoGenomics Inc. The current mfi is 53.38.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
NeoGenomics Inc Daily Money Flow Index (MFI) ChartNeoGenomics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for NeoGenomics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-26MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

NeoGenomics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of NeoGenomics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.614
Ma 20Greater thanMa 5014.297
Ma 50Greater thanMa 10015.027
Ma 100Greater thanMa 20015.852
OpenGreater thanClose14.340
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Neogenomics with someone you think should read this too:
  • Are you bullish or bearish on Neogenomics? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Neogenomics? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about NeoGenomics Inc

I send you an email if I find something interesting about NeoGenomics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about NeoGenomics Inc.

Receive notifications about NeoGenomics Inc in your mailbox!